Potential mechanisms for HPV vaccine-induced long-term protection

Gynecologic Oncology

Volumn 118, Issue 1 SUPPL. 1, 2010, Pages S2-

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

HPV vaccine; Immune memory; Long term HPV response; Vaccine induced immune response

Indexed keywords

ALUMINUM HYDROXIDE; DOUBLE STRANDED DNA; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHORYL LIPID A; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; MORBIDITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VERRUCA VULGARIS; WART VIRUS;

EID: 77952301743     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.04.002     Document Type: Review

References (36)

1. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S3/11-25
2. Lacey C.J., Lowndes C.M., and Shah K.V. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3 (2006) S3/35-41
3. Gardasil prescribing information. Available from:. http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf
4. Cervarix summary of product characteristics. Available from:. http://emc.medicines.org.uk/medicine/20204/SPC/Cervarix/
5. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2 (2009) 868-878
6. Paavonen J., Naud P., Salmeron J., Wheeler C., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
7. Palm N.W., and Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227 (2009) 221-233
8. Lanzavecchia A., and Sallusto F. Human B cell memory. Curr Opin Immunol 21 (2009) 298-304
9. McHeyzer-Williams L.J., Pelletier N., Mark L., Fazilleau N., and McHeyzer-Williams M.G. Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 21 (2009) 266-273
10. Wrammert J., and Ahmed R. Maintenance of serological memory. Biol Chem 389 (2008) 537-539
11. Slifka M.K., Antia R., Whitmire J.K., and Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 8 (1998) 363-372
12. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., and Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171 (2003) 4969-4973
13. Mamani-Matsuda M., Cosma A., Weller S., Faili A., Staib C., Garcon L., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111 (2008) 4653-4659
14. Ehrhardt G.R., Hijikata A., Kitamura H., Ohara O., Wang J.Y., and Cooper M.D. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med 205 (2008) 1807-1817
15. Ahuja A., Anderson S.M., Khalil A., and Shlomchik M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci 105 (2008) 4802-4807
16. Amanna I.J., Carlson N.E., and Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357 (2007) 1903-1915
17. Kennedy R.B., Ovsyannikova I.G., Jacobson R.M., and Poland G.A. The immunology of smallpox vaccines. Curr Opin Immunol 21 (2009) 314-320
18. Van Damme P., and Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5 (2007) 79-84
19. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
20. Banatvala J.E., and Van Damme P. Hepatitis B vaccine - do we need boosters?. J Viral Hepat 10 (2003) 1-6
21. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
22. Kanodian S., Fahey L.M., and Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 7 (2007) 79-89
23. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183 (2009) 6186-6197
24. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-492
25. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18 (2000) 1051-1058
26. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
27. Suzich J.A., Ghim S.J., Palmer Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci 92 (1995) 11553-11557
28. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
29. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
30. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
31. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26 (2008) 6844-6851
32. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (2009) 11975-11985
33. David M.P., Van Herck K., Hardt K., Tibaldi F., Dubin G., Descamps D., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modelling of sustained antibody responses. Gynecol Oncol 115 (2009) S1-S6
34. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
35. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
36. Rowhani-Rahbar A., Mao C., Hughes J.P., Alvarez F.B., Bryan J.T., Hawes S.E., et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 27 (2009) 5612-5619